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principle for PDT and SDT. Therefore, in vitro comparison of PDT 
and SDT effects can provide insight into SDT mechanism of action. 
We have investigated PDT and SDT effects on human melanoma 
and fibrosarcoma cell lines, previously exposed to 5 aminolevulinic 
acid (Ala), through cell proliferation, cell death, and gene expression 
analysis.
Patients (or Materials) and Methods: The human melanoma, A2058, 
and fibrosarcoma, HT-1080, cell lines were previously exposed to Ala 
(0.45 mM) for 12 and 4 hours, respectively. SW generated by a piezo-
electric device (Piezoson 100, Wolf) were used for SDT. In particular, 
A2058 were treated with an energy flux density (EFD) of 0.32 mJ/
mm2 for 1000 shots (4 shots/sec) while HT-1080 were treated with 
an EFD of 0.43 mJ/mm2 for 500 shots (4 shots/sec). A LED lamp at 
405 nm was used for PDT and both cell lines were treated for 5 min 
at 15 mW. Cell growth was evaluated by WST-1 assay, cell death by 
flow cytometric analysis with SYTOX Green and APC-Annexin V 
and mRNA expression by real-time RT-PCR.
Results: In A2058 both treatments determined a significant cell 
growth reduction even if SDT produced a progressive cell growth 
decrease compared with PDT reaching the greatest decrease at 72 
hours (P < 0.01). Moreover, cell death evaluation highlighted a 25% 
increase of apoptotic cells at 48 hours from SDT. Both PDT and 
SDT determined a significant overexpression of the pro-apoptotic 
gene BAX and of the genes involved in the oxidative stress, NQO1 
and SOD2. In HT-1080, SDT was more effective than PDT with a 
more significant increase of apoptotic cells compared with PDT (P < 
0.01).After both treatments a significant overexpression of the pro-
apoptotic gene APAF1 was observed.
Conclusion: After PDT and SDT a similar gene expression profile 
was observed in both cell lines, even though SDT seems more effective 
on fibrosarcoma cells and PDT on melanoma cells.
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Introduction: Curcumin possesses anticancer, anti-inflammatory, 
antioxidant, and antimicrobial properties. Curcumin has a poor oral 
bioavailability and solubility in plasma. Accordingly, various drug 
delivery systems, such as liposomal preparation, have been developed 
for intravenous administration. However, animal studies have shown 
dose-dependent hemolysis after infusion of liposomal curcumin. 
Because blood cells are the first point of contact for liposomal cur-
cumin when administered intravenously, we investigated the influence 
of curcumin on human red blood cell (RBC) morphology in vitro.
Patients (or Materials) and Methods: Whole blood buffered with 
EDTA was incubated with different concentrations (1, 10, 100 μ g/
mL) of free or liposomal formulations of curcumin. RBC morphology 
and mean cellular volume were examined after 30 minutes, 1 hour, 2 
hours, and 4 hours of incubation.
Results: Dose-dependent echinocyte formation was observed after 
incubation with free and liposomal Curcumin, with a threshold con-
centration of 10 µg/mL and peak effect after 30 minutes of incuba-
tion. Treatment with empty liposomes also resulted in RBC shape 
change. A concomitant increase in mean red blood cell volume was 
detectable.
Conclusion: Curcumin, liposomes and liposomal curcumin dose-
dependently change RBC morphology. This effect is additive and may 
represent a first sign of toxicity following intravenous administration.
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Introduction: In search for drugs that can target cancer cell microen-
vironment in as much as being able to halt malignant cellular trans-
formation, the natural dietary phytochemical curcumin was currently 
assessed in DMH-induced colorectal cancer rat model.
Patients (or Materials) and Methods: The study enrolled 50 animals 
divided into a control group (n = 10) and DMH-induced colorectal 
cancer control group (n = 20) (20 mg/kg.-body weight for 28 weeks) 
versus curcumin-treated group (n = 20) (160 mg/kg suspension daily 
oral for further 8 weeks).
Experimental Procedures: ACF Assay: The colonic lesion biopsies 
were stained by 30% methylene blue for light microscopic examina-
tion [using a 40 magnification to transluminate the specimens] in 
search for lesions fulfilling Mc Lellan and Bird criteria
Histopathological Examination: By using light microscopic 
assessment.
Biochemical Estimations in Colonic Tissues: Malondialdehyde 
(MDA) Assay, reduced glutathione (GSH) Assay, Cyclooygenase-2 
(COX-2) activity measurement, tumor necrosis factor-α (TNF-α 1 
Determination, platelet activating factor (PAF) activity measurement, 
transformaing growth factor-β (TGF-β ) determination:
Results: Treatment by curcumin succeeded to significantly decrease 
the percent of ACF and tended to normalize back the histologic 
changes retrieved in adenomatous and stromal cells induced by 
DMH. The drug also significantly elevated GSH and significantly 
reduced most of the accompanying biochemical elevations (namely 
MDA, TNF-α , TGF-β , and COX2) observed in colonic carcinoma-
tous tissue, induced by DMH, thus succeeding to revert that of MDA, 
COX2& TGF-β back to near normal as justified by being nonsignifi-
cantly altered compared with normal controls. The only exception 
was PAF, which was insignificantly altered by the drug.
Conclusion: When taken together, it could be concluded that cur-
cumin possess the potentiality to halt some of the orchestrated cross-
talk between cancerous transformation and its microenvironmental 
niche that contributes to cancer initiation, progression, and metasta-
sis in this experimental cancer colon model. Envisioning these merits 
to a drug with an already known safety preferentiality, awaits final 
results of current ongoing clinical trials, before curcumin can be 
added to the new therapeutic armamentarium of anticancer therapy.
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